Current best evidence on prescribed drugs

Drugdocs Logo

Current best evidence on prescribed drugs

HomeDrugsGlossaryAboutContact Us

Menu

HomeDrugsGlossaryAboutContact Us

Drugs A-Z

ABCDE FGHIJKLMNOPQRSTUVWXYZ

DRUGS

A

B

C

D

E

F

G

H

I

J

K

L

M

N

O

P

Q

R

S

T

U

V

W

X

Y

Z

Myrbetriq

Chemical Namemirabegron
Dosage FormTablet (oral; 25 mg, 50 mg); Suspension (oral; 8 mg/mL)
Drug ClassReceptor agonists
SystemUrinary
CompanyAstellas Pharma
Approval Year2012

Indication

  • For the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency
Last updated on 4/19/2022

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Myrbetriq (mirabegron) Prescribing Information.2012Astellas Pharma US Inc., Northbrook, IL
Document TitleYearSource
The use of mirabegron in neurogenic bladder: a systematic review. 2020World Journal of Urology
Comparative safety and efficacy of treatments for overactive bladder among older adults: a network meta‑analysis.2020Drugs and Aging
The relative efficacy and safety of mirabegron and onabotulinumtoxinA in patients with overactive bladder who have previously been managed with an antimuscarinic: a network meta-analysis.2019Urology
Updating the evidence on drugs to treat overactive bladder: a systematic review.2019International Urogynecology Journal
Efficacy and tolerability of mirabegron compared with antimuscarinic monotherapy or combination therapies for overactive bladder: a systematic review and network meta-analysis.2018European Urology
Real-world persistence and adherence to oral antimuscarinics and mirabegron in patients with overactive bladder (OAB): a systematic literature review.2018BMJ Open
Systematic review of combination drug therapy for non-neurogenic lower urinary tract symptom. 2018European Urology
Comparative assessment of the efficacy of onabotulinumtoxinA and oral therapies (anticholinergics and mirabegron) for overactive bladder: a systematic review and network meta‐analysis.2017BJU International
Document TitleYearSource
Diagnosis and treatment of non-neurogenic overactive bladder (OAB) in adults: an AUA/SUFU guideline (2019).2019American Urological Association
CUA guideline on adult overactive bladder.2017Canadian Urological Association